In Somaliq Pen 60 IU SunSci Pharmaceutical, the active ingredient is somatotropin, a growth hormone that is secreted in the human body by the anterior pituitary gland. The remedy is available in a convenient injection format. It makes sense to use it, first of all, for the formation of beautiful muscle relief.
Main effects of Somaliq Pen 60 IU SunSci Pharmaceutical
Somatotropin has many properties that are valued in sport. Especially in bodybuilding. In addition, it is able to increase the level of insulin-like growth factor, which also leads to significant results for athletes. The main effects of the drug:
- muscle building;
- fat burning;
- strengthening bones and connective tissue.
The mass gain is due to the fact that somatotropin has an anabolic effect and also slows down the destruction of muscles (anti-catabolic effect). The mass gain in this case occurs gradually and on a small scale. During one month of use, you can gain up to 5 kg of lean and hard muscles.
The fat-burning effect makes it possible to improve the relief of the silhouette and to obtain additional energy which is released when fats are oxidised. The results are especially noticeable on the abdomen, where after 6 weeks of using the drug, fat decreases.
The beneficial effect of the drug on bone tissue improves joint function, strengthens tendons and ligaments. It reduces the risk of injury during training. But the ability to stimulate the growth of these tissues makes the drug unacceptable for people in the period of active growth (if they do not have medical indications to take it).
Strengthening the immune system, rejuvenating the body, accelerating regeneration: all these are also the effects of Somaliq Pen 60 IU SunSci Pharmaceutical. But it does not increase strength and endurance, so it is not suitable for sports where these indicators are needed.
Possible negative effects
Side effects when taking growth hormone practically do not occur if there are no contraindications and individual sensitivity. When taking high doses, problems such as:
- pinched nerve surrounded by muscle or bone tissue;
- high blood sugar level;
- poor thyroid hormone production;
- excessive accumulation of fluid in tissues;
- high blood pressure.
In addition, when taking the drug, the fatigue threshold decreases. This means that the athlete tires faster and recovers longer after training. It does not interfere with life, but there may be some energy drop during training.
The remedy is contraindicated in people with malignant tumours. It can be taken by women, but not during pregnancy or lactation. It is also worth abandoning somatotropin in case of individual intolerance.
Rules of the course
Before use, be sure to consult with your doctor and exclude contraindications.
The drug is administered by injection. The dosage is chosen according to the physical performance of the athlete and his goals. The dose should be taken, as a rule, 3-4 times a week, more experienced athletes can use it every day. The best time to use it is before going to bed when there is a natural increase of growth hormone in the body.
PCT after the end of the growth hormone course is not necessary. It does not affect the work of sex hormones, does not affect libido and sexual function.
List of references
- Hindmarsh PC, Brook CGD. Bone mineral content and density in hypopituitary adults with isolated growth hormone deficiency: effects of growth hormone treatment. Clin Endocrinol (Oxf). 1991;34(5):391-396.
- Kniess F, Kohlmeyer U, Wollmann HA, et al. Adult patients with isolated growth hormone deficiency (GHD) after cessation of GHD therapy: is reinitiation of therapy advisable?. Horm Res. 2005;64(1):11-18.
- Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 2005;152(2):165-170.
- Mauras N, Attie KM, Reiter EO, Saenger P. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab. 2000;85(10):3653-3660.
- Varewijck AJ, Lamberts SWJ, Janssen JAMJL. Growth hormone receptor antagonists. Horm Res Paediatr. 2011;76(Suppl 1):53-57.